Business

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines

articleVeru Inc.March 12, 20245/company/veru-inc/news/veru-announces-the-appointment-of-louis-aronne-md-as-chief-medical-advisor-for-its-enobosarm-program-for-high-quality-weight-loss
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

About this update from Veru Inc.

[{"type":"text","content":"MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the appointment of Louis Aronne, MD, as Chief Medical Advisor and a member of the Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug for potentially higher quality weight loss. Dr. Louis Aronne is a leading authority on obesity and its treatment. He is the Sanford I. Weill Professor of Metabolic Research and the director of the Comprehensive Weight Control Center, a state-of-the-art, multidisciplinary obesity research, education, and treatment center in the division of Endocrinology, Diabetes & Metabolism at Weill Cornell Medicine. A graduate of Johns Hopkins University School of Medicine, Dr. Aronne is a founder and past chairman of the American Board of Obesity Medicine and a past president of The Obesity Society. He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte. He completed his internship and residency at Albert Einstein College of Medicine and Jacobi Medical Center, followed by a Henry J. Kaiser Family Foundation Fellowship in General Internal Medicine at New York-Presbyterian/Weill Cornell Medical Center. Dr. Aronne has been an investigator on more than 65 trials of obesity treatment modalities including medications, devices, and diets. He has authored more than 150 papers and book chapters on obesity and edited the National Institutes of Health’s Practical Guide to Obesity Treatment. He served as a consultant to the VA Weight Management/Physical Activity Executive Council in the development of the MOVE! Program, the nation’s largest medically based weight control program. Dr. Aronne has won many awards, including the 2015 Atkinson-Stern Award for Distinguished Public Service and 2021 Clinician of the Year from The Obesity Society, and several for medical teaching, including the Davidoff Prize from Albert Einstein College of Medicine and th...

More updates from Veru Inc.